Presentations & Publications

Targeting frameshift mutations with a Listeria monocytogenes immunotherapy drives neoantigen-specific anti-tumor immunity in the MC38 and CT26 mouse tumor models

UPLOADED:

March 2, 2018

Agonism of the CD137 co-stimulatory pathway synergizes with the Listeria monocytogenes-based immunotherapy, axalimogene filolisbac, to promote durable tumor regression in a murine HPV+ tumor model

UPLOADED:

February 25, 2018

Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform

UPLOADED:

February 5, 2018

Targeting shared hotspot cancer mutations with a Listeria monocytogenes immunotherapy induce potent anti-tumor immunity

UPLOADED:

February 1, 2018

Immunotherapy: A New Strategy for the Treatment of Cervical Cancer

UPLOADED:

January 22, 2018

Targeting frameshift mutations with a Listeria monocytogenes immunotherapy drives neoantigen-specific anti-tumor immunity in the MC38 and CT26 mouse tumor models

UPLOADED:

January 5, 2018

Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform

UPLOADED:

January 5, 2018

Targeting shared hotspot cancer mutations with a Listeria monocytogenes immunotherapy induce potent anti-tumor immunity

UPLOADED:

January 4, 2018

Molecular signatures of combination immunotherapy of prostate cancer using a Listeria-based PSA vaccine and radiation

UPLOADED:

November 13, 2017

Combination immunotherapy of murine prostate cancer using a Listeria-based PSA vaccine: immune correlates of efficacy and resistance development

UPLOADED:

November 13, 2017

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases and Advaxis' breaking news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.